FY2027 Earnings Forecast for Vaxart Issued By B. Riley

Vaxart, Inc. (NASDAQ:VXRT) – Equities research analysts at B. Riley issued their FY2027 earnings per share estimates for shares of Vaxart in a report issued on Monday, November 18th. B. Riley analyst M. Mamtani forecasts that the biotechnology company will post earnings of $0.09 per share for the year. The consensus estimate for Vaxart’s current full-year earnings is ($0.43) per share. B. Riley also issued estimates for Vaxart’s FY2028 earnings at $0.13 EPS.

Separately, Oppenheimer began coverage on Vaxart in a research note on Thursday, August 15th. They issued an “outperform” rating and a $4.00 price target on the stock.

Vaxart Trading Down 1.4 %

NASDAQ VXRT opened at $0.60 on Wednesday. The company has a market cap of $106.33 million, a PE ratio of -1.46 and a beta of 0.70. Vaxart has a 12 month low of $0.52 and a 12 month high of $1.54. The stock has a 50 day moving average of $0.78 and a 200-day moving average of $0.77.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in VXRT. Vanguard Group Inc. increased its position in Vaxart by 19.9% during the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company’s stock worth $10,984,000 after buying an additional 1,404,391 shares during the period. Tidal Investments LLC bought a new position in Vaxart during the 1st quarter worth $56,000. RA Capital Management L.P. bought a new position in shares of Vaxart in the first quarter worth $20,000,000. Sequoia Financial Advisors LLC bought a new position in shares of Vaxart in the second quarter worth $65,000. Finally, Monaco Asset Management SAM bought a new position in shares of Vaxart in the second quarter worth $402,000. Institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.